Our strategy is to extend the scope and the outreach of our services through partnerships while simultaneously progressing from transactional to more integrated relationships.
We are open to a wide range of partnering models, starting from simple co-referral and/or co-marketing, through joint service offering development, all the way to exclusive or preferred subcontractor status.
Our partners:
Best traditions of Finnish quality and integrity from the oldest and largest CRO in Finland (Kuopio/Oulu/Tampere/Turku/Helsinki, Finland)
Global service research organization offering integrated solutions from hit identification and lead generation to clinical development and market registration, with unique medicinal chemistry platform and research facilities in San Diego CA (USA), Kiev and Kharkov (Ukraine), Moscow, St-Petersburg and Jaroslavl (Russia)
High quality GLP-compliant service provider of histology, immunohistochemisty and in vitro research and testing based in Tampere, Finland
Integrated contract research for CNS cell and gene therapy preclinical drug development based in San Diego, CA, USA
Provider of multi-modality in vivo preclinical imaging services based in Grenoble, France
Dedication to research excellence and to spreading the knowledge through teaching (University of Helsinki, Finland)
Decades of marketing and sales experience in Life Sciences, head office in the heart of Europe (Martinsreid/Munich, Germany)
In terms of organization types, our natural partners are preclinical and clinical CROs, whose service portfolios we enhance through our unique offering. Simultaneously, we strive to join value networks of large or medium size pharmaceutical companies. Recognizing and supporting current trends toward outsourcing of R&D activities*, we aspire more integrated and lasting relationships with pharmaceutical companies.
We strongly believe in the uniqueness, timeliness and high potential of Neurotar's value proposition. By synergistically combining our innovative approach and know-how with industry experience and knowledge of established players, we can leverage capabilities and create greater efficiency and flexibility to solve problems jointly.
Last but not least, we are keen to maintain vital relationships with academia, which we see as a source of innovation, knowledge and inspiration.
*Moving Drug Development Outsourcing to a Higher Level: Tufts Center for Drug Development R&D Management Report. Page 4, Volume4, Number 3. June 2009.